Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ETON 
Eton Pharmaceuticals Inc (ETON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: ETON (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 126.38% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 454.29M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 3 | Beta 1.16 | 52 Weeks Range 9.77 - 23.00 | Updated Date 11/14/2025 |
52 Weeks Range 9.77 - 23.00 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate 0.11 | Actual 0.04 |
Profitability
Profit Margin -9.5% | Operating Margin (TTM) -0.17% |
Management Effectiveness
Return on Assets (TTM) 1.26% | Return on Equity (TTM) -34.17% |
Valuation
Trailing PE - | Forward PE 9.94 | Enterprise Value 446942341 | Price to Sales(TTM) 6.46 |
Enterprise Value 446942341 | Price to Sales(TTM) 6.46 | ||
Enterprise Value to Revenue 6.36 | Enterprise Value to EBITDA 635.76 | Shares Outstanding 26817535 | Shares Floating 17961044 |
Shares Outstanding 26817535 | Shares Floating 17961044 | ||
Percent Insiders 4.39 | Percent Institutions 62.83 |
Upturn AI SWOT
Eton Pharmaceuticals Inc
Company Overview
History and Background
Eton Pharmaceuticals, Inc. was founded in 2017. It focuses on developing and commercializing innovative pharmaceutical products for rare pediatric diseases.
Core Business Areas
- Pediatric Pharmaceuticals: Development and commercialization of products for unmet needs in pediatric rare diseases. Focus on injectables and liquid formulations. Commercializing products that are approved by the FDA.
Leadership and Structure
Sean Brynjelsen is the CEO of Eton Pharmaceuticals. The company has a management team focused on pharmaceutical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Alkindi Sprinkle: Alkindi Sprinkle (hydrocortisone granules in capsules) is approved for adrenocortical insufficiency in pediatric patients. Eton acquired U.S. rights. Competitors include generic hydrocortisone tablets and compounded formulations, though Alkindi Sprinkle provides a more precise and convenient dosage form for infants and young children. It's difficult to say what the market share is without having access to that private information.
- Betaine Anhydrous for Oral Solution: Betaine Anhydrous for Oral Solution is a medication used to treat homocystinuria. Difficult to determine market share, although the demand for this medication exists for those that need it. Other pharmaceuticals that accomplish the same objective are competitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The focus on rare diseases involves navigating smaller patient populations, orphan drug designations, and specialized regulatory pathways.
Positioning
Eton positions itself as a company focused on underserved pediatric populations and rare diseases. They aim to acquire, develop, and commercialize products with low competition.
Total Addressable Market (TAM)
The global rare disease market is estimated to be hundreds of billions of dollars. Eton focuses on a specific subset of this market, pediatric rare diseases, so their TAM is smaller but still significant. They are strategically positioning to address this TAM.
Upturn SWOT Analysis
Strengths
- Focus on rare pediatric diseases
- Experienced management team
- Proprietary formulations
- Acquisition and development strategy
Weaknesses
- Limited product pipeline (small number of products)
- Dependence on successful commercialization of key products
- Financial stability concerns in the past
- Small company resources compared to larger pharmaceutical companies
Opportunities
- Acquisition of additional products
- Expansion into new therapeutic areas
- Potential for orphan drug designations and exclusivity
- Strategic partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles and delays
- Competition from generic drugs or alternative therapies
- Product liability risks
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Competitor Data unavailable
Competitive Landscape
Eton's advantages lie in its focus on niche markets and proprietary formulations. Disadvantages include limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Acquisition data unavailable
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: Explain the strategic reasons behind the acquisition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on product acquisitions and regulatory approvals.
Future Projections: Future projections rely on successful commercialization of key products and potential acquisitions. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent initiatives include launching new products and pursuing regulatory approvals for pipeline products.
Summary
Eton Pharmaceuticals is a small, specialized pharmaceutical company targeting rare pediatric diseases. Its strengths are in acquiring and developing niche products with limited competition. The company faces challenges in commercializing products effectively and scaling operations with limited resources. Future success relies on expanding the product pipeline and securing regulatory approvals.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (unavailable)
- Market research reports (unavailable)
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Financial data and market share information may not be fully accurate or complete without access to proprietary sources. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eton Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Deer Park, IL, United States | ||
IPO Launch date 2018-11-13 | President, CEO & Director Mr. Sean E. Brynjelsen | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 31 | Website https://www.etonpharma.com |
Full time employees 31 | Website https://www.etonpharma.com | ||
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.